Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Greenberg

Showing results (131-140 of 156) with videos related to

Pageof 16
Sort By:
Haematologica|December 18, 2012
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemiaDaniel A Pollyea, James Zehnder, Steve Coutre, et al.
The New England Journal of Medicine|October 6, 2006
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletionAlan List, Gordon Dewald, John Bennett, et al.
Blood Advances|December 21, 2021
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndromeAaron T Gerds, Bart L Scott, Peter Greenberg, et al.
British Journal of Haematology|July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSSAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Leukemia & Lymphoma|September 17, 2015
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndromeRupa Narayan, Jacqueline S Garcia, Mary-Elizabeth M Percival, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618IJulia E Maxson, Samuel B Luty, Jason D MacManiman, et al.
JAMA Oncology|December 13, 2019
Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development StudyEhab Atallah, Brent Logan, Min Chen, et al.
British Journal of Haematology|November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup studyThomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
Leukemia Research|January 30, 2007
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conferencePeter Valent, Hans-Peter Horny, John M Bennett, et al.
Genes, Chromosomes & Cancer|September 25, 2018
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significanceJulie Schanz, Francesc Solé, Mar Mallo, et al.
Pageof 16

Showing results (131-140 of 156) with videos related to

Sort By:
Pageof 16
Haematologica|December 18, 2012
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemiaDaniel A Pollyea, James Zehnder, Steve Coutre, et al.
The New England Journal of Medicine|October 6, 2006
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletionAlan List, Gordon Dewald, John Bennett, et al.
Blood Advances|December 21, 2021
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndromeAaron T Gerds, Bart L Scott, Peter Greenberg, et al.
British Journal of Haematology|July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSSAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Leukemia & Lymphoma|September 17, 2015
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndromeRupa Narayan, Jacqueline S Garcia, Mary-Elizabeth M Percival, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618IJulia E Maxson, Samuel B Luty, Jason D MacManiman, et al.
JAMA Oncology|December 13, 2019
Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development StudyEhab Atallah, Brent Logan, Min Chen, et al.
British Journal of Haematology|November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup studyThomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
Leukemia Research|January 30, 2007
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conferencePeter Valent, Hans-Peter Horny, John M Bennett, et al.
Genes, Chromosomes & Cancer|September 25, 2018
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significanceJulie Schanz, Francesc Solé, Mar Mallo, et al.
Pageof 16